How do I model twelve months of orforglipron across supply routes?

I am comparing three suppliers on documentation rather than on price.

I have worked this out and I would like someone to find the error, because I suspect there is one.

My working so far, for the record, is below, and I am fairly sure the error is in the unit conversion rather than the algebra.

Is my approach right even if my number is wrong?

More usefully, a lane is a physical object with a temperature profile and a customs regime, and choosing one is a real decision rather than a shipping-option checkbox.

Personal-importation discretion varies more than people assume. Several jurisdictions operate a published enforcement-discretion policy for small quantities for personal use of unapproved products; several do not, and treat any importation of an unapproved medicinal product as an offence irrespective of quantity. The distinction is jurisdiction-specific and worth checking rather than inferring from a forum consensus.

Certificate red flags and what each implies

The diagnostic red flags, in rough order of how much they tell you: a certificate whose lot number does not match the vial; a certificate with no method section; a purity figure quoted to two decimal places with no chromatogram; a testing date that precedes the stated manufacturing date; identical certificates across nominally different lots; and "sterile filtered" offered in place of a sterility test. Each of those is a specific inference, not a vibe.

One qualification: independent testing tells you about the vial you sent. It tells you about the vial you kept only under an assumption of homogeneity that nobody has tested.

If a supplier will not send you a lot-specific certificate before you order, you have learned something useful at zero cost.

edited 14 Jul 2025 by orla_ferriter — updated for the 2026 guidance change

Specifically, the structural problem with a group buy is that the organiser typically holds both the money and the material, which means there is no point at which any participant has recourse. That is solvable, and it is solved by design rather than by trust.

What a verification listing at VendorInvestigate or a rating at PeptideMeter actually evidences is that some process was applied — which is more than nothing and considerably less than an audit. The useful question is what the process consists of and whether its inputs are independently obtained samples or vendor-supplied ones.

The consumer-protection question about a stablecoin transfer has a simple answer: you give up reversibility entirely. There is no chargeback, no acquirer, no dispute process. What you retain is the on-chain record, which proves that a transfer happened and to which address — useful for establishing that you paid, useless for getting the money back. That asymmetry is the whole risk profile.

The caveat is that none of this makes an unapproved product safe or lawful to use. It reduces one category of uncertainty — what is in the vial — and leaves every other category untouched.

Structure the group buy so that no single person is simultaneously the treasurer, the custodian and the arbiter. That one change removes most of the failure modes.

The part that matters: the question to ask is not whether a vendor is good but what evidence exists, of what kind, about which lots, from whom. Reputation is a compression of that evidence and it compresses badly.

Cost per milligram, worked honestly: a 10 mg vial at £34 is £3.40 per nominal milligram. If the content assay says 9.2 mg, that is £3.70 per actual milligram. If you then lose 4 µL of dead space per draw from a 2 mL fill across twenty draws, that is 80 µL or four per cent of the fill, taking you to £3.85. Add a £110 content assay amortised across the vial and it is £14.85 per milligram for the first vial of a new lot and £3.85 thereafter. The testing dominates, which is the actual argument for buying larger lots.

Mechanically, a defensible group-buy structure has three properties: the material is tested before it is split, the test is paid for from the pool rather than by the organiser, and the split is documented with photographs and a per-participant record of lot, volume and date. If any participant can reconstruct what they received from the records, a later dispute is resolvable. If not, it is not.

Independent testing costs have been stable enough over the past two years that amortisation arithmetic across a lot is worth doing before choosing a lot size, and the numbers usually favour a larger lot tested once over several small lots tested never.

The evidence you want is boring: the same result, from an independent laboratory, across more than one lot, over more than one year.

Start from what "research use only" actually means, because most of the downstream questions are answered by it. It means no release testing, no pharmacovigilance, no regulatory obligation to you, and no recourse.

The difference between a batch certificate and a vial certificate is a difference in what is being claimed. A batch certificate says "we tested some vials from this lot". A vial certificate says "we tested this vial". Neither is worthless; only one of them is about the object in your hand, and the gap between them is a sampling assumption nobody has quantified.

Test the first lot from any new supplier, set your accept threshold before the result arrives, and keep the certificate with the lot number and the date in one place.

Evaluate a supplier on the documentation they cannot fabricate cheaply, which in practice means lot-specific certificates from a laboratory that hosts its own reports and a testing history that spans more than one lot.

Lot-to-lot content variation of nine per cent between two nominally identical lots, both within a stated specification, is the single most common finding in independent testing and the least discussed. It is not fraud; it is the consequence of a fill process controlled to a tolerance rather than to a target. It is also the reason a per-lot content assay is worth more than a per-supplier reputation.

I would resist treating a long track record as evidence of current quality. Suppliers change synthesis partners, fill sites and staff, and a 2024 result is weak evidence about a 2026 lot.

Assume no recourse and plan accordingly. That assumption is both prudent and, in this context, accurate.